The Polypill - one pill for almost everything?
In 2003, British researchers first presented the idea of the polypill to the public. In addition to blood pressurelowering drugs, it contains other agents such as cholesterol-lowering drugs (statins) and aspirin (ASA). The researchers suggested that the polypill should be taken preventively by everyone from the age of 55 onward. Regardless of whether individuals had personal cardiovascular risk factors, the idea was that it would reduce the risk of cardiovascular disease.
The participants were divided into two groups. One group received the polypill, the other did not. During the observation period, 301 of 3,417 in the control group, but only 202 of 3,421 participants in the polypill group, suffered a serious cardiovascular event. These events included hospital admission for acute coronary syndrome, a fatal heart attack, sudden death, heart failure, a coronary artery revascularization procedure, as well as non-fatal and fatal stroke. That means 99 more people were spared such an event in the group taking the polypill than in the comparison group.
The smaller US study produced similar results. The 303 participants there were low-income and mostly unable to afford health insurance. They had to pay drug costs themselves, since there is no universal health coverage in the US. No participant had a cardiovascular disease at the start of the study. Again, participants were split into two groups: one received a polypill, the other did not. The studys observation period was twelve months. Medication adherence wassimilar to the Iranian studyover 80 percent.
The results were notable. In the treatment group the average systolic blood pressure fell by 9 mmHg, while in the comparison group without the polypill it fell by only 2 mmHg. LDL cholesterol also dropped much more in the polypill group: a 15 mg/dl reduction with the polypill versus only 4 mg/dl in the comparison group. So the mean LDL cholesterol fell by 11 mg/dl more in the treatment group.
Does that make the polypill a miracle drug for everyone?
As the two studies above show, a pill given preventively that contains several active ingredients can be beneficial in certain population groups. In both studies, participants came from groups that, for various reasons, have little access to medical care. Achieving an effect in these groups is therefore much more likely than in groups with good medical care. In the study populations, the chance of reaching people with undiagnosed high blood pressure or elevated blood lipids was relatively high. For healthy people in the group, taking a blood pressure drug isnt that problematic because it only lowers blood pressure a little. The one-size-fits-all or shotgun approach is viewed as more critical for the statins and aspirin included in the polypill, since aspirin can increase the risk of bleeding. Thisas well as the unnecessary use of statinsis seen as a risk thats difficult to predict accurately.
An earlier review by British and American physicians showed that the polypill was not more effective than the corresponding individual drugs. It also uses fixed doses of the individual components and therefore can't be adjusted as flexibly as prescribing the single drugs separately. This matters when targeting treatment to patients with cardiovascular risk factors. Healthy people over 55 benefit more from a healthy lifestyle than from the idea of giving the polypill preventively to everyone from that age.
Rethinking the polypill
In 2022 the concept of the previously little-noticed polypill was reconsidered. One study looked at a polypill made up of three drugs that nearly every patient receives as long-term medication after having a heart attack. These are: aspirin as a platelet inhibitor, an ACE inhibitor (ramipril), and the statin atorvastatin, each available in several strengths, resulting in six different strength combinations for the polypill.
The reduced pill burdenthat is, the smaller number of tablets patients have to takeled to significantly better adherence in the study group. After six months, 70.6% were taking their medication regularly; in the comparison group, which received the three components as separate drugs, only 62.7% did so. After two years, medication use improved slightly in both groups: 74.1% in the polypill group versus 63.2% in the control group regularly took the prescribed medications.
After about three years of follow-up, the improved adherence also had an effect on the occurrence of heart attacks, strokes, urgent procedures to clear narrowed vessels, and deaths from cardiovascular disease. In the treatment group, 9.5% of participants experienced such an event, while in the control group 12.7% were affected. The difference was especially clear for deaths: 5.8% of participants in the comparison group died during the follow-up period, while only 3.9% of those receiving the polypill did not reach the end of the follow-up period.
Because the polypill did not increase side effects or safety risks, it could be a viable option for secondary prevention after a heart attack.
Sources:
- https://www.nejm.org/doi/full/10.1056/NEJMoa1815359?query=featured_home
- https://www.aerztezeitung.de/Medizin/Mit-Polypille-weniger-Herzinfarkte-und-Schlaganfaelle-314849.html
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31791-X/fulltext
- https://www.assmann-stiftung.de/polypille-bewaehrt-sich-in-der-primaerpraevention-von-herzinfarkt-und-schlaganfall-319/
- https://www.test.de/Polypillen-Praktisch-aber-nicht-wirksamer-5196168-0/
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009868.pub3/abstract
- https://www.pharmazeutische-zeitung.de/polypille-ueberzeugt-in-langzeitstudie/
- https://www.aerzteblatt.de/nachrichten/136964/Sekundaerprophylaxe-Polypille-schuetzt-nach-Herzinfarkt-besser
- https://www.nejm.org/doi/pdf/10.1056/NEJMoa2208275
This article comes from BloodPressureDB – the leading app since 2011 that helps hundreds of thousands of people monitor their blood pressure every day.
Our content is based on carefully researched, evidence-based information and is continuously updated (as of 02/2026).
Author Sabine Croci is a certified medical assistant with many years of experience in internal medicine and cardiology practices as well as in outpatient care. Since 2015 she has led the editorial team at BloodPressureDB. With additional qualifications as a paramedic, first responder, and training in various therapy and emergency areas, she provides well-founded, practical, and reliably reviewed information.
Author Sabine Croci is a certified medical assistant with many years of experience in internal medicine and cardiology practices as well as in outpatient care. Since 2015 she has led the editorial team at BloodPressureDB. With additional qualifications as a paramedic, first responder, and training in various therapy and emergency areas, she provides well-founded, practical, and reliably reviewed information.
